Spondyloarthritis Research and Treatment Network (SPARTAN) 23rd Annual Meeting 2025

Advanced Spondyloarthritis, Psoriatic Arthritis & Immunology Update

The Spondyloarthritis Research and Treatment Network (SPARTAN) 23rd Annual Meeting 2025 provides a comprehensive review of the latest scientific discoveries, diagnostic advances, imaging techniques, and therapeutic developments in the management of Spondyloarthritis (SpA) and related immune-mediated disorders.

Designed for rheumatologists, immunologists, researchers, and healthcare professionals involved in the care of patients with inflammatory arthritis, this meeting explores the evolving understanding of disease pathogenesis, precision medicine, advanced imaging, clinical outcome measures, and emerging targeted therapies. The program highlights cutting-edge research into HLA-B27 biology, T-cell mediated inflammation, spatial transcriptomics, CAR-T therapy, and the complex relationship between spondyloarthritis and inflammatory bowel disease (IBD).

With expert-led lectures and scientific discussions, the meeting delivers practical insights that help clinicians improve diagnosis, monitoring, and treatment strategies for both adult and pediatric patients with spondyloarthritis.

Product Details

• Course: SPARTAN 23rd Annual Meeting 2025
• Date: May 9–10, 2025
• Format: 33 Videos + 1 PDF
• Size: 23.32 GB
• Access: On-Demand

Program Overview

Spondyloarthritis continues to be one of the most rapidly evolving fields within rheumatology. Advances in immunology, genetics, imaging, and biologic therapies are transforming the diagnosis and management of axial and peripheral SpA.

This meeting provides in-depth coverage of:

• Axial Spondyloarthritis (axSpA)
• Ankylosing Spondylitis
• Psoriatic Arthritis
• HLA-B27 Biology
• Immunopathogenesis
• MRI Imaging Advances
• Disease Activity Assessment
• Pediatric Spondyloarthritis
• Inflammatory Bowel Disease (IBD)
• Emerging Cellular Therapies
• Clinical Guidelines and Outcome Measures

The curriculum bridges basic science discoveries with real-world clinical applications to improve patient outcomes and support evidence-based care.

Learning Objectives

After completing this activity, participants will be able to:

• Analyze the molecular and immunologic mechanisms involved in spondyloarthritis.
• Understand the role of HLA-B27 and T-cell mediated pathways in disease development.
• Evaluate emerging treatment strategies, including advanced biologics and CAR-T therapies.
• Apply modern MRI protocols for diagnosis and disease monitoring.
• Utilize current outcome measures and disease activity indices in clinical practice.
• Interpret the latest ACR-SPARTAN-SAA recommendations.
• Identify sex-based and gender-related differences in disease presentation.
• Recognize the relationship between spondyloarthritis and inflammatory bowel disease.
• Optimize treatment strategies for both adult and pediatric patients.

Core Topics Covered

Spondyloarthritis Pathophysiology

• HLA-B27 Mechanisms
• Genetic Risk Factors
• T Cell Biology
• Cytokine Signaling
• Immunologic Pathways
• Disease Initiation and Progression

Precision Medicine & Translational Research

• Spatial Gene Profiling
• Biomarker Development
• Molecular Phenotyping
• Personalized Treatment Strategies
• Future Therapeutic Targets

Advanced Therapeutics

• Biologic Therapies
• JAK Inhibitors
• IL-17 Pathway Inhibitors
• TNF Inhibitors
• CAR-T Cell Therapy
• Emerging Immunologic Treatments

MRI & Imaging Advances

• MRI Protocol Optimization
• Early Disease Detection
• Radiographic Progression Assessment
• Axial Disease Monitoring
• Imaging-Based Outcome Measures

Clinical Assessment & Outcomes

• BASDAI Assessment
• ASDAS Scoring
• Disease Activity Monitoring
• Functional Outcome Measures
• Patient-Reported Outcomes

Psoriatic Arthritis

• Diagnostic Approaches
• Disease Heterogeneity
• Targeted Treatment Strategies
• Imaging Findings
• Clinical Management

Pediatric Spondyloarthritis

• Juvenile Disease Presentation
• Treatment Considerations
• Long-Term Outcomes
• Safety of Advanced Therapies

Inflammatory Bowel Disease & SpA

• Gut-Joint Axis
• Shared Immune Mechanisms
• Clinical Overlap Syndromes
• Integrated Management Approaches

Sex and Gender Differences

• Disease Manifestations
• Diagnostic Challenges
• Treatment Responses
• Personalized Care Considerations

Physical Examination & Clinical Skills

• Musculoskeletal Assessment
• Spinal Mobility Evaluation
• Clinical Monitoring Techniques
• Practical Examination Pearls

Educational Features

✔ Advanced Spondyloarthritis Education

✔ Latest SPARTAN Research Updates

✔ MRI & Imaging Guidance

✔ Emerging CAR-T Therapy Discussions

✔ Precision Medicine Approaches

✔ Adult & Pediatric Disease Coverage

✔ Immunology & Translational Science

✔ Evidence-Based Clinical Applications

Who Should Use This Course?

• Rheumatologists
• Immunologists
• Internal Medicine Physicians
• Pediatric Rheumatologists
• Researchers in Autoimmune Disease
• Rheumatology Fellows
• Advanced Practice Providers
• Healthcare Professionals Managing SpA

Why This Course Matters

Spondyloarthritis management is rapidly evolving through advances in genetics, immunology, imaging, and targeted therapies. This meeting provides clinicians with the latest evidence regarding disease mechanisms, diagnostic approaches, MRI interpretation, outcome assessment, and innovative treatments that are shaping the future of SpA care.

   Topics

1. Day 1 Classification and Clinical Manifestation of SpA- Deep Dive into IBP – Soha Dolatabadi, MD

2. Day 1 Disease Mechanisms in SpA- With and Without HLAB27 – Akihiro Nakamura, MD, PhD

3. Day 1 IBD and SpA – Reem Jan, MD, MBBS

4. Day 1 Individualize axSpA Treatment Options a Case Based Discussion- Lianne Gensler, MD

5. Day 1 MRI Workshop- Protocol, Finding, and Mimickers – Dennis Poddubnyy, MD, PhD, MSc

6. Day 1 Sex-Gender differences in Presentation and Manifestations of SpA – Lihi Eder, MD, PhD

7. Day 1 Slowing Radiographic Progression in Axial SpA – Marina Magrey, MD

8. Day 1 SpA Physical Exam Workshop – Philip Mease, MD

9. Day 2 Basic Science – Ruth Napier, PhD

10. Day 2 CAR-T (non-CD19) – Naoto Hirano, MD, PhD

11. Day 2 CLASSIC – Walter Maksymowych, MD, FRCP, FACP, University of Alberta, Alberta

12. Day 2 Clinical Science and Imaging – Jean Liew, MD, MS

13. Day 2 Clinical Trials – Abhijeet Danve, MBBS, MD, FACP

14. Day 2 IBD and SpA – Reem Jan, MD, MBBS

15. Day 2 Neuroimaging of Pain in Ankylosing Spondylitis Karen D. Davis, PhD, FCAHS, FRSC, Professor, Department of Surgery …

16. Day 2 SESSION I- Year in Review Moderators- Nigil Haroon, MD and Mohamed Bittar, MD

17. Day 2 SPARTAN Research Career Achievement and Distinguished Service Award Presentations

18. Day 2 T cells Animal Studies CD4-CD8-MAIT-NK-T – Judith Smith, MD, PhD

19. Day 2 T cells AS Patients – Michael Paley, MD, PhD

20. Day 3 ACR-SPARTAN-SAA Guidelines – Liron Caplan, MD, PhD

21. Day 3 BASDAI and its Components as Outcome Measures for axPsA – Pankti Mehta, MD, MBBS

22. Day 3 BASIS – Sibel Aydin, MD

23. Day 3 Imaging – Denis Poddubnyy, MD, PhD, MSc

24. Day 3 Mapping the PBR of SpA-associated Versus SpA-neutral HLA-B-27 Alleles, Using a High-throughput Genetic Screening …

25. Day 3 MRI neg axSpA does not exist – Lianne Gensler, MD, Atul Deodhar, MD

26. Day 3 New Pediatric SpA Classification Criteria – Pamela Weiss, MD, MSCE

27. Day 3 Safety of Prescription NSAIDs in Adults with IBD- Data from a Large Administrative Claims Cohort – Adam Mayer, MD

28. Day 3 Serum Proteomic Analysis of Cellular Immune Clusters in Psoriatic Arthritis – Steven Dang

29. Day 3 Spatial Gene Profiles for New Bone Formation in Ankylosing Spondylitis – Akihiro Nakamura, MD, PhD

30. Day 3 The Deubiquitinase TRABID is a Novel Therapeutic Target in Spondyloarthritis – Archita Srinath

31. Day 3 The Relationship Between HLA-B27 Positivity and Inflammatory Back Pain in the US Population – Mark Hwang, MD

32. Group Day 1

33. Group Day 2